RØYRVIK ET AL.was, by reverse <strong>genetic</strong>s, found to be located at chromosome b<strong>and</strong>s 2p15-16 <strong>in</strong>1993. 23 Later that year, two groups isolated the gene <strong>in</strong> question, MSH2, which,if mutated <strong>in</strong> the germl<strong>in</strong>e, causes HNPCC. 24,25 Studies of HNPCC tumors revealeda ladder of <strong>no</strong>vel alleles, rather than the expected loss of one allele expectedaccord<strong>in</strong>g to the two-hit hypothesis for the <strong>in</strong>activation of a potential tumorsuppressor gene. 10,12-14 In this manner, colorectal carc<strong>in</strong>ogenesis was tied to a<strong>no</strong>vel mechanism—defective mismatch repair. A variety of tumor types arefound <strong>in</strong> patients with HNPCC, the most common be<strong>in</strong>g colorectal, endometrial,gastric, <strong>and</strong> ovarian tumors. 26Tumors with MSI were <strong>in</strong>itially dubbed replication error tumors (RER+), <strong>and</strong>the classification was often based on analyses of a variable number of d<strong>in</strong>ucleotideloci. 10,12-14 Scor<strong>in</strong>g of a tumor as RER+ or RER- was somewhat arbitrary asit depended on the total number of loci analyzed. A consensus panel of fivemo<strong>no</strong>- <strong>and</strong> d<strong>in</strong>ucleotide markers (BAT25, BAT26—mo<strong>no</strong>nucleotide; D2S123,D5S346, D17S250 - d<strong>in</strong>ucleotide) was implemented later, <strong>and</strong> this so-called Bethesdapanel is <strong>no</strong>w the current st<strong>and</strong>ard for assess<strong>in</strong>g microsatellite <strong>in</strong>stability <strong>in</strong>both the hereditary <strong>and</strong> sporadic colorectal cancers. 27 The three d<strong>in</strong>ucleotidemarkers depend on the availability of correspond<strong>in</strong>g <strong>no</strong>rmal DNA <strong>in</strong> order toscore all affected tumors, whereas the BAT markers, be<strong>in</strong>g quasimo<strong>no</strong>morphic,can be more confidently used <strong>in</strong>dependent of <strong>no</strong>n-tumor DNA. Furthermore, theBAT markers are highly <strong>in</strong>formative, <strong>and</strong> therefore it has been suggested thatthese two, or even just BAT26, are sufficient for population-based diag<strong>no</strong>sticsaim<strong>in</strong>g to identify cases with potential germl<strong>in</strong>e cancer predisposition. 28It has long been suspected that patients with MSI-CRC have a better overallsurvival than those with MSS, 10,13,15 <strong>and</strong> it <strong>no</strong>w seems well-established that theformer phe<strong>no</strong>type is associated with an improved prog<strong>no</strong>sis to the degree of atleast 15% compared to patients with the latter type. 29 Diploidy is also a markerfor positive prog<strong>no</strong>sis, <strong>and</strong> though the majority of MSI-H tumors are diploid,ploidy <strong>and</strong> MSI status appear to be <strong>in</strong>dependent markers, as diploidy was <strong>in</strong>dicativeof <strong>in</strong>creased survival even with<strong>in</strong> the MSI group. 30III. DEFECTIVE MMR: THE GENERATOR OF THE MSI PHENOTYPEThe MSI phe<strong>no</strong>type is caused by faulty or lack<strong>in</strong>g mismatch repair prote<strong>in</strong>s ofthe MutL, MutS homolog repair systems, which then fail to correct <strong>in</strong>sertions <strong>and</strong>deletions primarily caused by replication slippage <strong>in</strong> microsatellites with smallrepetitive units. Replication slippage is liable to occur at such sequences; follow<strong>in</strong>ga transient, local dissociation of the nascent parental DNA str<strong>and</strong>, reassociatio<strong>no</strong>ccurs between misaligned complementary repeat units, therebylengthen<strong>in</strong>g or shorten<strong>in</strong>g the newly synthesized str<strong>and</strong>. 31-33 If the MMR systemis defective, such errors will <strong>no</strong>t be repaired <strong>and</strong> will accumulate <strong>in</strong> the cell.Most of the sporadic MSI tumors are caused by the silenc<strong>in</strong>g of MLH1 through232
TARGET GENES OF MSI COLORECTAL CANCERpromoter methylation, but some are caused by LOH/somatic mutation <strong>in</strong>MSH2. 34-40In the first step of eukaryotic mismatch repair, MSH2 recognizes the error<strong>and</strong> forms a heterodimer with either MSH3 or MSH6, depend<strong>in</strong>g on the nature ofthe irregularity. MSH3 is specific for <strong>in</strong>sertion/deletion (<strong>in</strong>del) loops of 2-4 nucleotides,while MSH6 is specific for s<strong>in</strong>gle nucleotide loops or mismatches. Acomplex of DNA, MutS homologs, <strong>and</strong> ATP recruits a heterodimer of MLH1<strong>and</strong> PMS2, which displaces the ma<strong>in</strong> processive DNA polymerase <strong>and</strong> the slid<strong>in</strong>gclamp PCNA, before recruit<strong>in</strong>g base excision mach<strong>in</strong>ery to remove the tract<strong>in</strong> which the mismatch occurs. As the b<strong>in</strong>d<strong>in</strong>g partners of MSH2 <strong>and</strong> MLH1 arecompletely dependent on them, any defect <strong>in</strong> MSH2, MSH3, <strong>and</strong> MSH6 will effectively<strong>in</strong>hibit the functions of PMS2 (as well as PMS1 <strong>and</strong> MLH3, of uncerta<strong>in</strong>functional relevance) for MLH1. 41,42IV. CELLULAR CONSEQUENCES OF DEFECTIVE MMRDefects <strong>in</strong> the systems above are <strong>no</strong>t <strong>in</strong> themselves carc<strong>in</strong>ogenic, they simplyprovide the occasion for accumulation of <strong>in</strong>dels <strong>in</strong> the exist<strong>in</strong>g microsatellites <strong>in</strong>the ge<strong>no</strong>me—the result<strong>in</strong>g changes <strong>in</strong> some of the affected genes enables the <strong>in</strong>cipienttumor to acquire necessary carc<strong>in</strong>omatous characteristics such as evasio<strong>no</strong>f apoptosis, lack of dependency of extracellular/extratumoral growth signals, <strong>in</strong>sensitivityto anti-growth signals, angiogenesis <strong>and</strong> unlimited scope for replication.43 The search for such target genes of MSI-CRC first bore fruit <strong>in</strong> the shapeof the tumor suppressor gene TGFRII <strong>in</strong> 1995, 44,45 two years after the MSI phe<strong>no</strong>typewas described for familial cancers, 10,12,14 to be followed by what were tobecome the other “ca<strong>no</strong>nical” target genes, partly by virtue of their early discovery<strong>and</strong> subsequent frequent assessment: BAX, IGFIIR, MSH3, <strong>and</strong> MSH6.46 47 48In a stepwise model of tumorigenesis, the existence of “secondary mutators” likeMSH3 <strong>and</strong> MSH6 * has been suggested, given that they are DNA repair prote<strong>in</strong>sprone to frameshift mutations themselves, <strong>and</strong> may, when mutated, exacerbatethe phe<strong>no</strong>type. 49,50 MRE11, through its probable MLH1-related <strong>in</strong>volvement <strong>in</strong> 3’nick-directed MMR, may have a similar effect. 51Cancers of the hereditary <strong>no</strong>n-polyposis colorectal cancer (HNPCC) type, themost common be<strong>in</strong>g colorectal <strong>and</strong> endometrial, 26 also display microsatellite <strong>in</strong>stability(see above), <strong>and</strong> have similar mutational spectra to the sporadic MSIcancers, though the <strong>in</strong>itial <strong>genetic</strong> flaws <strong>in</strong> these cases are germl<strong>in</strong>e mutations <strong>in</strong>the mismatch repair systems. 49V. LITERATURE SURVEY OF TARGET GENESIn order to survey k<strong>no</strong>wn <strong>and</strong> putative target genes, a search was performed <strong>in</strong>* This, naturally, can only be the case if the tumor possesses functional MSH2.233
- Page 1 and 2:
Novel genetic and epigenetic altera
- Page 3 and 4:
TABLE OF CONTENTSACKNOWLEDGEMENTS .
- Page 5 and 6:
ACKNOWLEDGEMENTSThe present work ha
- Page 7 and 8:
Prefacetechnology[3]. This new tech
- Page 10 and 11:
SummaryThe subgroup of carcinomas w
- Page 12 and 13:
Introduction“Epigenetic inheritan
- Page 14 and 15:
Introductionamino acid change it is
- Page 16 and 17:
Introductionmethylation during embr
- Page 18 and 19:
IntroductionDNA is most of the time
- Page 20 and 21:
IntroductionFigure 5. DNA methylati
- Page 22 and 23:
IntroductionFigure 6. Incidence rat
- Page 24 and 25:
IntroductionFigure 8. Tumor staging
- Page 26 and 27:
Introductioninasmuch as 80% of colo
- Page 28 and 29:
IntroductionInstabilities involved
- Page 30 and 31:
Introductionthere seems to be a fid
- Page 32 and 33:
Introductionsevere alterations are
- Page 34 and 35:
Introductionpopulation-wide screeni
- Page 36 and 37:
IntroductionFigure 12. Present and
- Page 38 and 39:
RESULTS IN BRIEFPaper Ia. “DNA hy
- Page 40 and 41:
Results in Briefinstability, and se
- Page 42 and 43:
Results in BriefUnivariate survival
- Page 44 and 45:
Discussionseveral factors, and full
- Page 46 and 47:
Discussionlow threshold, we increas
- Page 48 and 49:
DiscussionIt may seem like unnecess
- Page 50 and 51:
Discussionthan 96% DHPLC do not sta
- Page 52 and 53:
DiscussionFigure 13. Mutation detec
- Page 54 and 55:
DiscussionClinical impact of molecu
- Page 56 and 57:
Discussionmarkers with a very high
- Page 58 and 59:
Discussionchromosomes in metaphase[
- Page 60 and 61:
DiscussionThese examples underline
- Page 62 and 63:
Discussiongenes. One is based on mu
- Page 64 and 65:
CONCLUSIONSWe have identified novel
- Page 66 and 67:
Future PerspectivesMolecular risk a
- Page 68 and 69:
REFERENCES1. Breasted J (1930) The
- Page 70 and 71:
References29. Deng G, Chen A, Pong
- Page 72 and 73:
References57. Al-Sukhni W, Aronson
- Page 74 and 75:
References84. Kunkel TA (1993) Nucl
- Page 76 and 77:
ReferencesLeggett B, Levine J, Kim
- Page 78 and 79:
References133. Lind GE, Thorstensen
- Page 80 and 81:
References156. Meling GI, Lothe RA,
- Page 82 and 83:
ReferencesT, Song X, Day RH, Sledzi
- Page 84 and 85:
References196. Honda S, Haruta M, S
- Page 86 and 87:
ORIGINAL ARTICLESAPPENDIXAppendix I
- Page 89 and 90:
GASTROENTEROLOGY 2007;132:1631-1639
- Page 91:
Paper IbGuro E Lind, Terje Ahlquist
- Page 94 and 95:
Journal of Translational Medicine 2
- Page 96 and 97:
Journal of Translational Medicine 2
- Page 98 and 99:
Journal of Translational Medicine 2
- Page 100 and 101:
Journal of Translational Medicine 2
- Page 102 and 103:
Journal of Translational Medicine 2
- Page 105:
Paper IITerje Ahlquist, Guro E Lind
- Page 108 and 109:
BackgroundMost cases of colorectal
- Page 110 and 111:
ADAMTS1 CDKN2A CRABP1 HOXA9 MAL MGM
- Page 112 and 113:
pseudogene, leading to a high rate
- Page 114 and 115:
strands. Proc Natl Acad Sci U S A 1
- Page 116 and 117: concomitant absence of transcript a
- Page 119 and 120: Volume 10 Number 7 July 2008 pp. 68
- Page 121 and 122: 682 RAS Signaling in Colorectal Car
- Page 123 and 124: 684 RAS Signaling in Colorectal Car
- Page 125 and 126: 686 RAS Signaling in Colorectal Car
- Page 127: Table W2. Detailed Somatic Events o
- Page 131 and 132: Identification of RCC2 as a prognos
- Page 133 and 134: INTRODUCTIONMicrosatellite instabil
- Page 135 and 136: unselected series of primary tumors
- Page 137 and 138: specificity, i.e. that they only am
- Page 139 and 140: On the assumption that DNA repair a
- Page 141 and 142: In order to ensure that gene mutati
- Page 143 and 144: Figure 2. Mutation frequency differ
- Page 145 and 146: and TAF1B (0.50), ACVR2A and ASTE1
- Page 147 and 148: Multivariate analysesA multivariate
- Page 149 and 150: When comparing our findings of muta
- Page 151 and 152: The test series included a low numb
- Page 153 and 154: entering M-phase remains to be seen
- Page 155 and 156: 12. Duval A, Reperant M, Hamelin R
- Page 157 and 158: 34. Martineau-Thuillier S, Andreass
- Page 159: AppendicesAppendix I:List of abbrev
- Page 163 and 164: Critical Reviews TM in Oncogenesis,
- Page 165: TARGET GENES OF MSI COLORECTAL CANC
- Page 169 and 170: TARGET GENES OF MSI COLORECTAL CANC
- Page 171 and 172: TARGET GENES OF MSI COLORECTAL CANC
- Page 173 and 174: TARGET GENES OF MSI COLORECTAL CANC
- Page 175 and 176: TARGET GENES OF MSI COLORECTAL CANC
- Page 177 and 178: TARGET GENES OF MSI COLORECTAL CANC
- Page 179 and 180: TARGET GENES OF MSI COLORECTAL CANC
- Page 181 and 182: TARGET GENES OF MSI COLORECTAL CANC
- Page 183 and 184: TARGET GENES OF MSI COLORECTAL CANC
- Page 185 and 186: TARGET GENES OF MSI COLORECTAL CANC
- Page 187 and 188: TARGET GENES OF MSI COLORECTAL CANC
- Page 189 and 190: TARGET GENES OF MSI COLORECTAL CANC
- Page 191: TARGET GENES OF MSI COLORECTAL CANC